• 1
    Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, et al. Fabry's disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 2006; 8: 53948.
  • 2
    Zarate YA, Hopkin RJ. Fabry's disease. Lancet 2008; 372: 142735.
  • 3
    Desnick R, Ioannou Y, Eng C. α-galactosidase A deficiency: Fabry's disease. In: ScriverCR, SlyWS, ValleD, editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill; 2001. p. 373374.
  • 4
    Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999; 281: 24954.
  • 5
    Kornreich R, Desnick RJ, Bishop DF. Nucleotide sequence of the human α-galactosidase A gene. Nucleic Acids Res 1989; 17: 33012.
  • 6
    Wang RY, Lelis A, Mirocha J, Wilcox WR. Heterozygous Fabry's women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med 2007; 9: 3445.
  • 7
    Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, et al. Females with Fabry's disease frequently have major organ involvement: lessons from the Fabry's Registry. Mol Genet Metab 2008; 93: 11228.
  • 8
    Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M, for the European FOS Investigators. Natural history of Fabry's disease in females in the Fabry's Outcome Survey. J Med Genet 2006; 43: 34752.
  • 9
    Birklein F. Mechanisms of neuropathic pain and their importance in Fabry's disease. Acta Paediatr Suppl 2002; 91: 347.
  • 10
    Dutsch M, Marthol H, Stemper B, Brys M, Haendl T, Hilz MJ. Small fiber dysfunction predominates in Fabry's neuropathy. J Clin Neurophysiol 2002; 19: 57586.
  • 11
    Moller AT, Jensen TS. Neurological manifestations in Fabry's disease. Nat Clin Pract Neurol 2007; 3: 95106.
  • 12
    Schiffmann R, Scott LJ. Pathophysiology and assessment of neuropathic pain in Fabry's disease. Acta Paediatr Suppl 2002; 91: 4852.
  • 13
    Ortiz A, Oliveira JP, Waldek S, Warnock DG, Cianciaruso B, Wanner C, and the Fabry's Registry. Nephropathy in males and females with Fabry's disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant 2008; 23: 16007.
  • 14
    Schiffmann R, Warnock DG, Banikazemi M, Bultas J, Linthorst GE, Packman S, et al. Fabry's disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 2009; 24: 210211.
  • 15
    Ortiz A, Cianciaruso B, Cizmarik M, Germain DP, Mignani R, Oliveira JP, et al. End-stage renal disease in patients with Fabry's disease: natural history data from the Fabry's Registry. Nephrol Dial Transplant 2010; 25: 76975.
  • 16
    Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A, et al. Cardiac manifestations of Anderson-Fabry's disease: results from the international Fabry's Outcome Survey. Eur Heart J 2007; 28: 122835.
  • 17
    Pierre-Louis B, Kumar A, Frishman WH. Fabry's disease: cardiac manifestations and therapeutic options. Cardiol Rev 2009; 17: 315.
  • 18
    Fellgiebel A, Muller MJ, Ginsberg L. CNS manifestations of Fabry's disease. Lancet Neurol 2006; 5: 7915.
  • 19
    Sims K, Politei J, Banikazemi M, Lee P. Stroke in Fabry's disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry's Registry. Stroke 2009; 40: 78894.
  • 20
    Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, et al, for the Fabry Disease Clinical Trial Study Group. Agalsidase-β therapy for advanced Fabry's disease: a randomized trial. Ann Intern Med 2007; 146: 7786.
  • 21
    Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, et al. Sustained, long-term renal stabilization after 54 months of agalsidase β therapy in patients with Fabry's disease. J Am Soc Nephrol 2007; 18: 154757.
  • 22
    Schiffmann R, Askari H, Timmons M, Robinson C, Benko W, Brady RO, et al. Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry's disease who are on long-term biweekly dosing. J Am Soc Nephrol 2007; 18: 157683.
  • 23
    Linthorst GE, Bouwman MG, Wijburg FA, Aerts JM, Poorthuis BJ, Hollak CE. Screening for Fabry's disease in high risk populations: a systematic review. J Med Genet 2010; 47: 21722.
  • 24
    Hopkin RJ, Bissler J, Banikazemi M, Clarke L, Eng CM, Germain DP, et al. Characterization of Fabry's disease in 352 pediatric patients in the Fabry's Registry. Pediatr Res 2008; 64: 5505.
  • 25
    Ramaswami U, Whybra C, Parini R, Pintos-Morell G, Mehta A, Sunder-Plassmann G, et al, for the FOS European Investigators. Clinical manifestations of Fabry disease in children: data from the Fabry's Outcome Survey. Acta Paediatr 2006; 95: 8692.
  • 26
    Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Stork S, et al. Long-term effects of enzyme replacement therapy on Fabry's cardiomyopathy: evidence for a better outcome with early treatment. Circulation 2009; 119: 5249.
  • 27
    Hilz MJ, Brys M, Marthol H, Stemper B, Dutsch M. Enzyme replacement therapy improves function of C-, Aδ-, and Aβ-nerve fibers in Fabry's neuropathy. Neurology 2004; 62: 106672.
  • 28
    Valeriani M, Mariotti P, Le Pera D, Restuccia D, De Armas L, Maiese T, et al. Functional assessment of A δ and C fibers in patients with Fabry's disease. Muscle Nerve 2004; 30: 70813.
  • 29
    Gomes I, Nora DB, Becker J, Ehlers JA, Schwartz IV, Giugliani R, et al. Nerve conduction studies, electromyography and sympathetic skin response in Fabry's disease. J Neurol Sci 2003; 214: 215.
  • 30
    Laaksonen SM, Roytta M, Jaaskelainen SK, Kantola I, Penttinen M, Falck B. Neuropathic symptoms and findings in women with Fabry's disease. Clin Neurophysiol 2008; 119: 136572.
  • 31
    Moller AT, Bach FW, Feldt-Rasmussen U, Rasmussen AK, Hasholt L, Sommer C, et al. Autonomic skin responses in females with Fabry's disease. J Peripher Nerv Syst 2009; 14: 15964.
  • 32
    Schaefer RM, Tylki-Szymanska A, Hilz MJ. Enzyme replacement therapy for Fabry's disease: a systematic review of available evidence. Drugs 2009; 69: 2179205.
  • 33
    Cimaz R, Coppa GV, Kone-Paut I, Link B, Pastores GM, Elorduy MR, et al. Joint contractures in the absence of inflammation may indicate mucopolysaccharidosis. Pediatr Rheumatol Online J 2009; 7: 18.
  • 34
    Cimaz R, Guillaume S, Hilz MJ, Horneff G, Manger B, Thorne JC, et al. Awareness of Fabry disease among rheumatologists: current status and perspectives. Clin Rheumatol 2010. E-pub ahead of print.